Can a JAK inhibitor tame the immune attack in NMOSD?

NCT ID NCT05792462

Ongoing Disease control Sponsor: Tianjin Medical University General Hospital Source: ClinicalTrials.gov ↗

First seen Aug 03, 2026 · Last updated Aug 12, 2026 · Updated 3 times

Summary

This early-phase trial tests whether baricitinib, an oral drug that blocks certain immune signals, can reduce relapses in people with neuromyelitis optica spectrum disorder (NMOSD). NMOSD is a rare autoimmune condition where the immune system attacks the optic nerves and spinal cord, causing vision loss and weakness. The study will give participants 4 mg of baricitinib daily for up to 96 weeks, tracking relapse frequency and changes in disability. The goal is to see if this approach is safe and may help control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: baricitinib
What this could lead to: If effective, baricitinib could offer a new oral treatment option to reduce relapses and slow disability in people with NMOSD.
What could go wrong: This is an early-phase trial with only 11 participants, so results may not apply broadly. Baricitinib may also have side effects, and its benefit in NMOSD is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NMO SPECTRUM DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuromyelitis optica

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NMO SPECTRUM DISORDER

Contacts and locations

Locations

Tianjin Medical University General Hospital

Tianjin, Tianjin Municipality, 300052, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.